Missouri · Schedule I · HB 1717 passed House · SB 1767 companion
Missouri's psilocybin story is four failed bills and the fifth — HB 1717 — finally over the House.
Kansas City and St. Louis. After four sessions of psilocybin study bills dying in committee or on the calendar — 2022, 2023, 2024, and 2025 — Representative Richard West's HB 1717 passed the Missouri House 137-11 in April 2026. The vehicle is a vets/first-responders study, amended in March 2026 to add ibogaine. Companion HB 1643 covers a broader therapeutic carveout for adults 21+ (PTSD, MDD, SUD, end-of-life) and was Reported Do Pass 7-2-2 from committee in February 2026. The state's medical-research anchor is Washington University School of Medicine in St. Louis, which administered the first legal Missouri psilocybin dose in 2019 and runs ongoing neuroimaging studies. Schedule I status is unchanged outside the bill's framework.
90-second quick read · research companion
Need the full research version?
This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.
Four tries, then five
How Missouri's HB 1717 finally crossed the House
Four sessions filed psilocybin study bills in Missouri. Each one died — in committee, on the calendar, at adjournment. The fifth attempt cleared the floor on the strength of a vets/first-responders framing.
Four sessions tried. Four bills died. The fifth — HB 1717 — broke through the House in April 2026, 137 to 11.
HB 2570 / SB 707
Filed, died in committee
HB 1154 / SB 583
Filed, died in committee
HB 1830 / HB 2850
Filed, died on calendar
HB 829 / SB 211
Filed, died at adjournment
HB 1717
PASSED HOUSE 137-11
Why this shape
A study bill, not a therapy framework
HB 1717 is structured as a research authorisation, not an access programme. Veterans and first responders are the named beneficiary populations. The Senate companion is SB 1767. The broader therapeutic carveout — HB 1643 — covers adults 21+ across PTSD, major depressive disorder, substance-use disorder, and end-of-life. It would also establish a manufacturer registry by November 1, 2026.
- Vets and first responders only — HB 1717 names the eligible populations specifically. The framing has carried four legislators across four sessions of trying.
- Ibogaine added late — HB 1717 was amended in the last week of March 2026 to add ibogaine alongside psilocybin. The vehicle is broader than the original 2022 draft.
- Right-to-try revision — HB 1643's broader therapeutic framework revises Missouri's existing right-to-try statute. It also establishes a manufacturer registry deadline.
- Senate action pending — HB 1717's House passage is unprecedented. The Senate has not yet acted. Companion SB 1767 was first-read on February 26, 2026.
Four cities
Where the bill, the research, and the patients live
Missouri's psilocybin geography is the Kansas City corridor on the western edge, St. Louis as the medical-research anchor on the eastern edge, Springfield as the southwestern population centre, and Columbia for the Mizzou academic-medical context.
Kansas City
MO/KS metro split
~510K MO side. Inside HB 1717's framework. Pairs with the Kansas side at /states/kansas/kansas-city/.
Kansas City pageSt. Louis
WashU research anchor
Washington University School of Medicine. First legal Missouri psilocybin dose 2019. Ongoing fMRI studies.
St. Louis pageSpringfield
SW Missouri
~170K. Greene County. Principal Ozarks population centre. HB 1717 statewide if enacted.
Springfield pageColumbia
MU Mizzou
Boone County. MU School of Medicine — a plausible site for any HB 1717 vets/first-responders study.
Columbia pageCommon questions
Missouri psilocybin FAQ
Q · 01
Is psilocybin legal in Missouri?
No. Psilocybin is Schedule I under Missouri's Comprehensive Drug Control Act. Possession outside an authorised clinical research framework is a criminal offence. If HB 1717 enacts, the resulting vets/first-responders study would not change broader possession penalties.
Q · 02
What is HB 1717?
HB 1717 is Representative Richard West's (R-Wentzville) psilocybin and ibogaine study bill for veterans and first responders. It passed the Missouri House 137-11 in April 2026 — the first time a Missouri psilocybin study bill has reached the Senate after four prior session attempts.
Q · 03
What about HB 1643?
HB 1643 (Rep. Matthew Overcast, R-District 155) is a broader therapeutic carveout for adults 21+ covering PTSD, major depressive disorder, substance-use disorder, and end-of-life conditions. It revises Missouri's right-to-try statute and establishes a manufacturer registry by November 1, 2026. Reported Do Pass 7-2-2 on February 26, 2026.
Q · 04
Is there any current legal access in Missouri?
Only through federally authorised clinical research. Washington University School of Medicine in St. Louis runs psilocybin neuroimaging studies under FDA Investigational New Drug authorisation. The first legal Missouri psilocybin dose was administered at WashU in 2019. Trial participation is study-specific.
Q · 05
Have any Missouri cities decriminalised psilocybin?
No. Kansas City, St. Louis, Springfield, Columbia, and other Missouri municipalities have not adopted psilocybin decriminalisation or deprioritisation ordinances. Missouri carries zero decriminalised cities.
While HB 1717 moves to the Senate
iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.